Market-ready Advicenne Seeks Partners and €40m VC Funds
With a focus on pediatric neurology and nephrology, Dr Luc-André Granier, founder, CEO and medical director of the 10-year old Nimes, France-based Advicenne Pharma SA, tells Scrip how he is looking to raise €40m from VCs in the next two years, while looking for partners to complete development of and commercialize his market-ready and late Phase II assets.
You may also be interested in...
Also, Advicenne doubles its fundraising to date; Michael Gilman-helmed Arrakis raises a $38m Series A; Breath spins out with $46m; and Spero gets $51.7m for novel antibacterials.
La Jolla Pharmaceutical grossed $125m, Inspyr Therapeutics signs a deal to raise up to $100m, Ionis's Akcea makes $100m IPO plans, and $64m in cash for SutroVax tops recent venture capital rounds.
Switzerland’s fast-growing critical-care company Primex has submitted for approval what it believes is the first oral solution for the mild to moderate sedation of anxious children undergoing surgical and diagnostic procedures, with a launch in Europe penciled in for a year’s time.